Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit

Haojian Zhang
Wuhan University

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Cancer Biology Commons, Cell Biology Commons, Cells Commons, Hemic and Immune Systems Commons, Hemic and Lymphatic Diseases Commons, Neoplasms Commons, Therapeutics Commons, and the Translational Medical Research Commons

Repository Citation
Zhang H, Li S. (2019). Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit. Open Access Publications by UMMS Authors. https://doi.org/10.1002/sctm.18-0247. Retrieved from https://escholarship.umassmed.edu/oapubs/3839

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMMS Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit

HAOJIAN ZHANG, b, b SHAOGUANG LI c, c

Key Words. Cancer stem cells • BCR-ABL • Chronic myeloid leukemia • Bone marrow • Leukemia

ABSTRACT

Cancer stem cells play a critical role in disease initiation and insensitivity to chemotherapy in numerous hematologic malignancies and some solid tumors, and these stem cells need to be eradicated to achieve a cure. Key to successful targeting of cancer stem cells is to identify and functionally test critical target genes and to fully understand their associated molecular network in these stem cells. Human chronic myeloid leukemia (CML) is well accepted as one of the typical types of hematopoietic malignancies that are derived from leukemia stem cells (LSCs), serving as an excellent model disease for understanding the biology of LSCs and developing effective, selective, and curative strategies through targeting LSCs. Here, we discuss LSCs in CML with a focus on identification of unique biological features of these stem cells to emphasize the feasibility and significance of specific targeting of LSCs while sparing normal stem cell counterparts in leukemia therapy. Stem Cells Translational Medicine 2019;00:1–7

SIGNIFICANCE STATEMENT

Molecular mechanisms by which leukemia stem cells (LSCs) survive and self-renew are poorly understood, and an effective anti-LSC therapeutic strategy for chronic myeloid leukemia is yet to be developed. In discussing the establishment of anti-LSC methods in the present study, much attention has been paid to the identification of fundamental biological differences between LSCs and normal hematopoietic stem cells (HSCs) with a goal of eradicating LSCs specifically to avoid or minimize unwanted cytotoxic side effects on normal HSCs. The authors hope to provide convincing arguments to emphasize that it is feasible to specifically target LSCs while sparing normal HSCs.

INTRODUCTION

Cancer stem cells are believed to be associated with cancer initiation and insensitivity to chemotherapy in numerous hematologic malignancies and some solid tumors involving the breast, brain, pancreas, colon, lung, and prostate, and need to be eradicated for achieving a cure [1–9]. Although the cancer stem cell theory cannot be used to explain the pathological features of all types of cancers, it has become clear that some major forms of human hematopoietic malignancies such as chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) are derived from leukemia stem cells (LSCs) that are responsible for leukemia initiation, progression, and relapse [10]. To develop effective and curative anti-stem-cell strategies, CML and AML are good model diseases for understanding the molecular biology of LSCs, and a key initial step is to identify and functionally test critical target genes and the molecular pathways they communicate with in LSCs. In this article, we intend to focus on CML because we have more direct evidence showing the biology of LSCs and their insensitivity to tyrosine kinase inhibitors (TKIs), the first-line treatments for CML patients.

LSCs are leukemia-initiating cells with the capacity to self-renew, differentiate, and remain in a state of quiescence [1, 2]. In CML, a myeloproliferative disease that originates from an abnormal hematopoietic stem cell (HSC) harboring the Philadelphia chromosome (Ph+) [11], functional LSCs in mice reside in a cell population that does not express cell lineage markers but express both c-Kit and Sca-1 (Lin-c-Kit*Sca-1+, LSK) [12], recapitulating the cell surface markers expressed on normal HSCs. LSCs in human CML also reside in the HSC population [13], displaying phenotypically Lin−CD34−CD38−CD90+ with some specific surface markers such as interleukin-1 receptor accessory protein (IL1RAP) and CD26 [14, 15].

At a molecular level, gene expression profiling studies using leukemia mice and human patient samples have shown some dramatic changes in...
Leukemia Stem Cells for Therapeutic Benefit

Although eradication of LSCs in the treatment of CML patients is critically required for survival and proliferation by LSCs in CML, yet to be achieved, we believe that for therapeutic benefit, it is critical to identify unique biological features of LSCs for developing effective strategies aiming to kill LSCs while protecting normal HSCs. In this article, we will pay much attention to discussing the potential strategies for targeting LSCs more specifically.

**BIOLOGICAL FEATURES OF LSCS**

With self-renewal and multipotency at the hub of what defines a LSC (Fig. 1), the major focus of current and future research should be on studying the biology of LSCs with a goal of fully understanding the underlying molecular and cellular processes.

**Leukemia Stem Cells Display Unique Cellular State**

The developmental processes and biological characteristics of normal HSCs have been extensively investigated in the past decades. It is commonly accepted that normal HSCs are largely in a state of quiescence with autophagy-dependent, glycolytic, and tightly controlled levels of protein synthesis [17–20]. Leukemogenesis occurs because of the serial genetic and epigenetic alterations that transform normal HSC/progenitor cell into LSCs [21, 22]. This transformation changes the steady-state biology of normal HSCs, leading to self-renewal, differentiation arrest, and increased survival of LSCs [26].

**Figure 1.** Biological properties of normal HSCs and LSCs. Normal HSCs have three major biological features or stem cell properties: self-renewal, multipotency, and quiescence. After acquiring genetic lesions, HSCs undergo cellular transformation to become LSCs that retain the major stem cell properties of HSCs with enhanced signaling activities and also acquire some unique biological features. These biological features define the cellular states of HSCs and LSCs, and provide opportunities to develop strategies for specifically targeting LSCs while sparing normal HSCs. Abbreviations: HSC, hematopoietic stem cell; LSC, leukemia stem cell.

Besides inheriting common stem cell characteristics, LSCs also have some unique functional changes, as exemplified by LSCs that undergo reprogrammed cellular metabolism, a hallmark of cancers [31]. Fatty acid metabolism enzyme stearoyl-CoA desaturase (Scd1) is an endoplasmic reticulum enzyme in a family of Δ9-fatty acid desaturase isoforms and catalyzes the biosynthesis of monounsaturated fatty acids from saturated fatty acids, which are the most abundant fatty acids present in mammalian organisms [32]. Fatty acid synthesis has been found to be associated with tumorigenesis and tumor progression [33]. However, we found that Scd1 is downregulated in LSCs and plays a tumor-suppressive role in LSCs with no notable inhibitory effect on normal HSCs [34], suggesting a cell-content-dependent role of fatty acid in cancer. In addition, BCAT1, a cytosolic aminotransferase for branched-chain amino acids is aberrantly activated and functionally required for AML LSCs [35]. It also plays an essential role in the progression of CML chronic phase to blast crisis through induction of cell differentiation arrest [36]. Furthermore, a metabolic analysis on both stem-cell-enriched (CD34+ and CD34+CD38−) and differentiated cells (CD34−) derived from CML patients reveals that CML LSCs rely on upregulated oxidative metabolism for their survival [37].

Another example for the functional changes in LSCs is that Alox5, a lipid-metabolic gene encoding the arachidonate 5-lipoxygenase, is required for survival of CML LSCs and essential for CML development [38].

**Heterogeneity of LSCs**

Cellular heterogeneity is one of well-recognized characteristics of both normal HSCs and LSCs. With respect to the clonal heterogeneity of differentiation and self-renewal properties in normal HSCs, two distinct subtypes of HSCs (lymphoid-deficient and lymphoid-myeloid-balanced) have been identified and distinguished by assessing the contributions of individual HSCs to the circulating cell lineages in serial transplantation experiments [39, 40]. Also, the post-transplant clonal analysis of HSC expansion suggests that both HSC subtypes display an extensive but variable self-renewal activity with occasional interconversion [40]. Similarly, heterogeneity of LSCs has been recognized. Using the SCL-tTA/BCR-ABL mouse model of CML, a recent study reveals that long-term repopulation and leukemia-initiating capacity of LSCs after transplantation is restricted to
BCR-ABL-expressing long-term HSCs (LT-HSCs) with remarkable heterogeneity [41]. This heterogeneity of BCR-ABL-expressing LT-HSCs is determined based on comparing the global gene expression between leukemic and nonleukemic LT-HSCs by RNA sequencing. A higher level of MPL expression is found in some leukemic LT-HSCs with enhanced JAK/STAT signaling and cell proliferation in response to stimulation of the thrombopoietin (TPO) receptor MPL [41]. In contrast, BCR-ABL-expressing LT-HSCs with low MPL expression show a reduced response to TPO-induced JAK/STAT signaling and decreased leukemogenic potential, suggesting that this subtype of LSCs may be insensitive to inhibition by JAK inhibitors. Therefore, this study identifies MPL expression levels as a key determinant of heterogeneous leukemia-initiating capacity of LSCs in CML [41]. Importantly, the heterogeneity of LSCs is thought to contribute to leukemia initiation, progression, and relapse. It has been reported that residual BCR-ABL+ stem cells persist in some CML patients who have maintained long-term remission, and after discontinuing the treatment with a TKI, molecular relapse occurs in a significant number of CML patients [12, 13, 42–45]. The discrepancies in leukemogenic potential between MPL-high and MPL-low LSCs could be explained by the heterogeneity of CML LSCs, which likely reflects uniqueness of LSCs determined by the intrinsic molecular machinery or extrinsic microenvironment.

**INSSENSIVITY OF LEUKEMIA STEM CELLS TO DRUG THERAPY AND POSSIBLE MECHANISMS**

BCR-ABL TKIs including imatinib mesylate (Gleevec, Novartis) are highly effective in controlling chronic phase CML, but they fail to eradicate leukemia-initiating cells or LSCs in CML mice [12] and patients [13, 46, 47]. Clinically, a complete and sustained molecular remission (undetectable levels of BCR-ABL transcripts) is difficult to attain even after a complete cytogenetic remission achieved through imatinib treatment [48–51], suggesting that imatinib and probably other BCR-ABL kinase inhibitors can effectively kill highly proliferating leukemia cells but are incapable of eradicating LSCs for cure. An anti-LSC strategy other than the use of a TKI alone needs to be developed to eradicate LSCs, and the success of this approach relies on uncovering the underlying mechanisms by which LSCs survive drug therapy (Fig. 2).

**LSCs Are Insensitive to Inhibition by TKIs**

TKIs have become first-line drugs in treating CML, and the majority of patients achieve a complete hematological response [52–55]. However, the fact that clinical relapse occurs in a significant number of CML patients once treatment is interrupted [56] indicates that CML LSCs are insensitive to drug therapy. In support of this idea, cells from CML patients in chronic phase...
were labeled with carboxy-fluorescein diacetate succinimidyldiester to track cell division, and imatinib treatment caused eradication of almost all dividing CD34+ cells, but the nonproliferating quiescent cells remained [13]. In addition, BCR-ABL+CD34+ cells persisted in CML patients who achieved complete cytogenetic response with imatinib treatment [57]. Furthermore, although treatment with TKIs dramatically prolonged the survival of CML mice, the mice eventually died of this disease [12], indicating the failure of TKIs to completely eradicate leukemia cells. The incomplete therapeutic response of CML cells to TKI inhibition in mice is related to the inability of imatinib to eradicate LSCs [58]. Together, these studies indicate that CML LSCs are insensitive to TKI treatment, prompting us to provide a mechanistic explanation for TKI resistance of LSCs. It should be pointed out that the TKI resistance of LSCs we discuss here is not relevant to TKI-resistant BCR-ABL kinase domain mutations.

LSC Survival Is Not Dependent on BCR-ABL Kinase Activity

The failure of TKIs to completely eradicate CML LSCs suggests that survival of these LSCs is not dependent on BCR-ABL kinase activity. We provided a biochemical evidence showing that dasatinib, a second-generation TKI, inhibits BCR-ABL phosphorylation in BCR-ABL-expressing HSCs but fails to kill these stem cells [12], suggesting that LSCs likely use BCR-ABL kinase activity-independent pathways for survival. Similarly, BCR-ABL kinase activity is inhibited by TKIs in CD34+CD38− and CD34+CD38+ cell populations from newly diagnosed CML patients, and phospho-CRKL, which is stimulated by BCR-ABL kinase activity, is reduced upon inhibition of BCR-ABL kinase activity as detected by immunobLOTS of sorted quiescent (Ki67−) and cycling (Ki67+) cells [46]. Additionally, in human CML CD34+ cells cultured in serum-free media and treated with dasatinib, phospho-CRKL is completely inhibited by dasatinib, but the abilities of proliferation and self-renewal of the cells are retained [44]. These results demonstrate the insensitivity of CML LSCs to inhibition by TKIs is not due to the inability of TKIs to inhibit BCR-ABL kinase activity in LSCs. It is likely that BCR-ABL also activates other signaling pathways in a kinase activity-independent manner, and it will be critical to identify and test these pathways in survival regulation of LSCs.

BCR-ABL Kinase Activity-Independent Pathways in LSCs

As described above, compared with proliferative leukemia cells, CML LSCs are much less sensitive to inhibition by TKIs even in the absence of BCR-ABL kinase domain mutations that cause TKI resistance. We believe that when its kinase activity is suppressed by TKIs, BCR-ABL can still activate some pathways that render CML LSCs insensitive to TKI inhibition. As a result, the cells continue to survive, whereas BCR-ABL kinase activity is inhibited by TKIs, indicating that this TKI-insensitive pathway activated by BCR-ABL must be targeted to lead to eradication of LSCs. This idea is supported by the essential role of Alox5 in survival regulation of CML LSCs [38]. We show that Alox5 is upregulated by BCR-ABL and essential for CML development, but this upregulation is not reduced by TKI treatment. These results provide a mechanistic explanation for why CML LSCs are insensitive to inhibition of BCR-ABL kinase activity by TKIs even in the absence of BCR-ABL kinase domain mutations. Thus, Alox5 represents a unique pathway that cannot be shut down upon kinase inhibition by TKIs in BCR-ABL signaling and plays a critical role in mediating TKI resistance in LSCs. Another example is that B lymphocyte kinase is significantly downregulated by BCR-ABL in a kinase activity-independent manner, and this pathway plays a tumor-suppressive role in regulating the survival of CML LSCs [59]. Again, the abovementioned intrinsic mechanism provides one explanation for the insensitivity of LSCs to TKIs. It should be mentioned that some studies also suggest that TKI resistance of LSCs is related to receiving extrinsic signals from bone marrow niche with which LSCs interact [60]. Further research in this area will be beneficial for developing new strategies for eradicating LSCs.

Strategies for Targeting LSCs

It is obvious that one of the best strategies for inhibiting LSCs is to target the key genes that are required for survival regulation of LSCs but not normal HSCs. It may also be acceptable that as a potential anti-LSC target, a candidate gene is required more by LSCs than by normal HSCs, providing a therapeutic window for inhibiting LSCs more specifically. In other words, the unique biological features of LSCs provide better opportunities for specifically targeting LSCs while sparing normal stem cell counterparts.

Targeting Critical Molecular Pathways of LSCs

In CML, some genes have been shown to be involved in survival regulation of LSCs, including Wnt/β-catenin [24, 58], Hedgehog [25], Bim-1 [61, 62], p53 [63], p16Ink4a [64], p19ARF [65], Pten [66], PML [67], PP2A [68], TGF-β/FOXO [29], Musashi [69], Alox5 [38], SIRT1 [70], Alox15 [71], and Hif1α [27]. However, only some of these studies emphasize specific targeting of LSCs, although it is hoped that the target genes required for both LSCs and normal HSCs would only produce tolerable side effects after normal HSCs are inhibited to a certain degree. In fact, several chemical inhibitors against these targets have been developed and studied. For example, pharmacological blockade of Hedgehog signaling by clinical-grade SMO inhibitors (such as GDC-0449 and LDE225) [25, 72, 74], inhibition of the TGFβ-FoxO pathway by Ly364947 [29], inactivation of BCL6 by the retro-inverso BCL6 peptide inhibitor R1-BPI [75], and suppression of autophagy by pharmacological inhibitors [76] have been shown to inhibit CML development by inhibiting LSCs. Inhibition of the HIF1α pathway by echinomycin is also effective in suppressing LSCs [27, 77]. It will be important to further evaluate these inhibitors for their clinical benefit in treating leukemia patients.

We have been focusing on identification of target genes uniquely or more specifically required for cellular functions by LSCs but not normal HSCs. In fact, we have identified Alox5 as a key gene that regulates the function of LSCs but not normal HSCs, because Alox5 deficiency or inhibition of function of this gene impairs survival and self-renewal of LSCs and prevents the initiation of BCR-ABL-induced CML with no significant inhibitory effect on normal HSC function [38]. Additionally, Scd1 plays a tumor-suppressive role specifically in LSCs, and we and others have tested and shown the inhibitory or apoptotic effect of PPARγ agonists on CML LSCs [34, 78]. Mechanistically, LSC apoptosis induced by the PPARγ agonist rosiglitazone is associated with an increased expression of Scd1, Pten, and p53 [34]. Furthermore, deficiency of Alox15 and inhibition of Alox15 function lead to remarkable inhibition of...
of LSCs with much less effect on normal HSCs in CML mice [71]. Finally, it has been recently shown that simultaneous targeting of P53 (by blocking its degradation) and c-MYC (by suppressing its transcription) has more dramatic inhibitory effect on CD34– cells from CML patients than on normal CD34+ cells [79]. Taken together, these results support our belief that it is realistic and approachable to identify and target critical molecular pathways that play an essential role more specifically in LSCs. In other words, it is possible to develop new therapeutic strategies aiming to specifically eradicate LSCs while sparing normal HSCs.

Targeting Epigenetic Properties of LSCs

Besides acquiring genetic lesions, LSCs also undergo epigenetic changes. Targeting of epigenetic regulators has recently shown to be effective in eliminating CML LSCs. EZH2, the catalytic subunit of polycomb repressive complex 2, is overexpressed in CML LSCs [80, 81], which is associated with extensive reprogramming of H3K27me3 targets in the cells. Genetic inactivation of EZH2 in conventional conditional knockout mice and through CRISPR/Cas9-mediated gene editing reduces survival of LSCs and prolongs survival of CML mice [80]. An EZH2-specific inhibitor promotes apoptosis of LSCs from CML patients without impairing normal HSCs, which is more predominant when the combined treatment with an EZH2 inhibitor and a TKI is used [81]. These findings suggest a promising epigenetic-based therapeutic strategy for more specifically targeting LSCs.

Targeting LSCs Using Antibodies Against Cell Surface Antigens

Although cell surface markers expressed on CML LSCs and normal HSCs are similar, the levels of expression for some markers are much higher in LSCs than in HSCs, providing an opportunity for preferentially targeting LSCs using antibodies. For example, a gene-expression profiling study in CML CD34+ cells and cord blood CD34+ cells transduced with retroviral BCR-ABL showed that expression of IL1RAP is upregulated in the cells [82]. In this study, normal (Ph−) and leukemic (Ph+) cells within the CML CD34+CD38− cell compartment were distinguished by fluorescence in situ hybridization, and the results showed that the CML CD34+CD38− IL1RAP+ cells were Ph+, whereas CML CD34+CD38+IL1RAP− cells were almost exclusively Ph−. Furthermore, a long-term culture-initiating cell assays showed that Ph+ and Ph− candidate CML stem cells could be prospectively separated based on IL1RAP expression, and an anti-IL1RAP antibody could be used as a target on CML CD34+CD38− cells to induce antibody-dependent cell-mediated cytotoxicity. Another example is CD33 that was found to have a much higher expression in CD34+CD38−CD123− cells from CML patients than in normal CD34+CD38− stem cells [83]. Interestingly, colony formation and long-term culture-initiating cell assays showed that the CD33-targeting drug gemtuzumab/ozogamicin produced growth inhibition of leukemic progenitor cells. These studies support a strong scientific premise for targeting CML LSCs using antibodies against cell surface antigens. Other examples include expression of cell surface molecules that are linked to signaling pathways in LSCs. In particular, CD25, a STAT5-dependent cell surface marker, regulates the growth of CML LSCs, which is associated with the PI3K/mTOR pathway [84, 85]. It is hopeful that CD25 could be a legitimate target for eradicating CML LSCs.

CONCLUSION

A full understanding of biology of LSCs allows exploiting the critical differences between LSCs and normal HSCs at a molecular level. This approach will subsequently lead to identification of unique biological features of LSCs for developing effective therapeutic strategies aiming to target LSCs specifically while sparing normal HSCs. Although there are still some difficult hurdles to cross, we believe that we are much closer to applying anti-LSC strategies for achieving durable disease remission or even a cure. However, the reality is that an effective anti-LSC therapy is yet to be developed, implying difficult challenges we are facing. Based on the recent scientific advances made in the LSC field, it is hopeful that we begin to understand how LSCs use unique molecular pathways to maintain their abilities of survival and self-renewal, which will lead to future clinical trials for testing new anti-LSC strategies.

ACKNOWLEDGMENTS

H.Z. is supported by grants from the National Key Research and Development Program of China (2017YFA0505600), the National Natural Science Foundation of China (81722003 and 81870124), the Wuhan Science and Technology Program for Application and Basic Research Project (2018060401011325), and the Hubei Provincial Natural Science Foundation for Creative Research Group (2018CFA018). S.L. is supported by National Institutes of Health (R01CA176179, R01CA222590, and R21CA209298).

AUTHOR CONTRIBUTIONS

H.Z., S.L.: manuscript writing. H.Z. and S.L.: contributed to the final revision and approval of the manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicated no potential conflicts of interest.

REFERENCES

1 Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci 2005;1044:1–5.
2 Wang JC, Dick JE. Cancer stem cells: Lessons from leukemia. Trends Cell Biol 2005;15:494–501.
3 Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737.
4 Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983–3988.
5 Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821–5828.
6 Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111–115.
7 Li C, Heidt DG, Dalera P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030–1037.
8 Kim CF, Jackson EL, Woofenden AE et al. Identification of bronchioalveolar stem
cells in normal lung and lung cancer. Cell 2005;121:823–835.
9. Goldstein AS, Huang J, Guo C et al. Identification of a cell of origin for human prostate cancer. Science 2010;329:568–571.
10. Hnuty BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005;5:311–321.
11. Zhao H, Hong S, Witte ON. The BCR-ABL story: Bench to bedside and back. Annu Rev Immunol 2004;22:247–306.
12. Hu Y, Swerdlow S, Duffy TM et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006;103:16870–16875.
13. Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319–326.
14. Wisniewski D, Affer M, Willshire J et al. Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90 +CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia. Blood Cancer J 2011;1:e36.
15. Herrmann H, Sadowik I, Cerny-Reiterer S et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 2014;123:3935–3942.
16. Radich JP, Dai H, Mao M et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:27994–27999.
17. Cabezás-Wallscheid N, Buettner F, Sommerkamp P et al. Vitamin A-retinoid acid signaling regulates hematopoietic stem cell dormancy. Cell 2017;169:807–823 e819.
18. Ho TT, Warr MR, Adelman ER et al. Autophagy maintains the metabolism and function of you and old stem cells. Nature 2017;543:205–210.
19. Takubo K, Nagamatsu G, Kobayashi CI et al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell 2013;12:49–61.
20. Signer RA, Magee JA, Salic A et al. Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature 2014;509:49–54.
21. Bowman RL, Busque L, Levine RL. Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell 2018;22:157–170.
22. Li S, Garrett-Bakelman FE, Chung SS et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med 2016;22:792–799.
23. Savona M, Talpaz M. Getting to the stem of chronic myeloid leukemia. Nat Rev Cancer 2008;8:341–350.
24. Zhao C, Blum J, Chen A et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007;12:529–541.
25. Zhao C, Chen A, Jamieson CH et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776–779.
26. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-ABL-expressing cell lines and peripheral blood cells derived from leukemia patients. J Immunol 1997;159:4720–4728.
27. Deckelbaum Y, Xi HP et al. HIF1alpha is required for survival maintenance of myeloid leukemia stem cells. Blood 2012;119:2595–2607.
28. Cheloni G, Tanturi M, Tusa I et al. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor alrancifil. Blood 2017;130:655–665.
29. Naka K, Hoshii T, Muraguchi T et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukemia. Nature 2010;463:676–680.
30. Holyoke TL, Vetrie D. The chronic myeloid leukemia stem cell: Stemming the tide of persistence. Blood 2017;129:1595–1606.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:644–674.
32. Scaglia N, Igal RA. Stearoyl-CoA desaturase is required in the control of proliferation, anchorage-independent growth, and survival in human transformed cells. J Biol Chem 2005;280:25339–25349.
33. Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 2016;16:732–749.
34. Hanahan D, Lo H, Ho N et al. Scd1 plays a tumor-suppressive role in survival of leukemia stem cells and the development of chronic myeloid leukemia. Mol Cell Biol 2012;32:1776–1787.
35. Raffel S, Falcone M, Kreisel N et al. BCA1 restricts alphakG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 2017;551:384–388.
36. Hattori A, Tsunoda M, Konuma T et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukemia. Nature 2017;545:500–505.
37. Kuntz EM, Baquer P, Michie AM et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat Med 2017;23:1234–1240.
38. Chen Y, Hu Y, Zhang H et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009;41:783–792.
39. Dykstra B, Kent D, Bowie M et al. Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell 2010;7:273–283.
40. Benz C, Copley MR, Kent DG et al. Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell 2012;10:273–283.
41. Zhao H, Qi H, Li Y et al. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. J Clin Invest 2016;126:975–991.
42. Mahon FX, Rea D, Guilhot J et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STiM) trial. Lancet Oncol 2010;11:1029–1035.
43. Chomel JC, Bonnet ML, Sorel N et al. Leukemic stem cell persistence in chronic myeloid leukaemia patients with sustained undetectable molecular residual disease. Blood 2011;118:3657–3660.
44. Hamilton AHG, Schenonek M, Zhang B et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012;119:1501–1510.
45. Ross DM, Branford S, Seymour JF et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24:1719–1724.
46. Corbin AS, Agarwal A, Loriaux M et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011;121:3946–3955.
47. Marley SB, Deininger MW, Davidson RJ et al. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 2000;28:551–557.
48. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–1432.
49. O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
50. Lin F, Drummond M, O’Brien S et al. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. Blood 2003;102:1143.
51. Drummond MW, Lush CJ, Vickers MA et al. Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia 2003;17:463–465.
52. Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207–3213.
53. Guilhot F, Apperley J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143–4150.
54. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303–2309.
55. Ottmann O, Dombret H, Martinelli G et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood 2007;110:2309–2315.
56. Cortes J, O’Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving
a molecular response. Blood 2004;104:2204–2205.
57 Bhata R, Holtz M, Niu N et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701–4707.
58 Hu Y, Chen Y, Douglas L et al. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009;23:109–116.
59 Zhang H, Peng C, Hu Y et al. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet 2012;44:861–871.
60 Arrigoni E, Del Re M, Galimberti S et al. Concise Review: Chronic myeloid leukemia: Stem cell niche and response to pharmacologic treatment. Stem Cells Translational Medicine 2018;7:305–314.
61 Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukemic stem cells. Nature 2003;423:255–260.
62 Park IK, Qian D, Kiel M et al. Bmi-1 is required for maintenance of adult self-renewing hematopoietic stem cells. Nature 2003;423:302–305.
63 Molofsky AV, Pardal R, Morrison SJ. Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol 2004;16:700–707.
64 Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr Opin Genet Dev 2003;13:77–83.
65 Molofsky AV, He S, Bydon M et al. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005;19:1432–1437.
66 Yilmaz OH, Valdez R, Theisen BK et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475–482.
67 Ito K, Bernardi R, Morotti A et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008;453:1072–1078.
68 Neviani P, Santanam R, Trotta R et al. The tumor suppressor Pp2a is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355–368.
69 Ito T, Kwon HY, Zimdahl B et al. Regulation of myeloid leukemia by the cell-fate determinant Musashi. Nature 2010;466:765–768.
70 Li L, Wang L, Li L et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012;21:266–281.
71 Chen Y, Peng C, Abraham SA et al. Arachidonate 15-lipoxigenase is required for chronic myeloid leukemia stem cell survival. J Clin Invest 2014;124:3847–3862.
72 Dierks C, Beigi R, Guo GR et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008;14:238–249.
73 Irvine DA, Zhang B, Kinstrie R et al. Dereguated hedgehog pathway signaling is inhibited by the smoothened antagonist LD225 (Sonidegib) in chronic phase chronic myeloid leukemia. Sci Rep 2016;6:25476.
74 Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood 2012;119:2196–2204.
75 Hurtz H, Hatzis K, Czerchieti L et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 2011;208:2163–2174.
76 Bellodi C, Lidonnici MR, Hamilton A et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109–1123.
77 Wang Y, Liu Y, Malek SN et al. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011;8:399–411.
78 Prost S, Relouzat F, Spentchian M et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature 2015;525:380–383.
79 Abraham SA, Hopcroft LE, Carrick E et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature 2016;534:341–346.
80 Xie H, Peng C, Huang J et al. Chronic myelogenous leukemia-initiating cells require polycistron group protein EZH2. Cancer Discov 2016;6:1237–1247.
81 Scott MT, Korfi K, Saffrey P et al. Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discov 2016;6:1248–1257.
82 Jaraa M, Johnels P, Hansen N et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 2010;107:16280–16285.
83 Herrmann H, Cerny-Reiterer S, Gleixner KV et al. CD34(+)/CD38(−) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica 2012; 97:219–226.
84 Kobayashi CI, Takubo K, Kobayashi H et al. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood 2014;123:2540–2549.
85 Sadownik I, Hoelbl-Kovacic A, Herrmann H et al. Identification of CD25 as STAT5 dependent growth regulator of leukemic stem cells in Ph+ CML. Clin Cancer Res 2016;22: 2051–2061.